Association between immunity and prognostic factors in early stage breast cancer patients before adjuvant treatment

被引：0
|
作者：
Marzio E.E. Sabbioni
Hans Peter Siegrist
Marisa Bacchi
Jürg Bernhard
Monica Castiglione
Beat Thürlimann
Hervé Bonnefoi
Lucien Perey
Richard Herrmann
Aron Goldhirsch
Christoph Hürny
机构：
[1] University HospitalInselspital,Medical Division Lory
[2] Medizinisch-chemisches Labor,Haus
[3] IBCSG,Medical Department C
[4] Biometrics,Gynecology Department
[5] Ares-Serono International S.A.,Oncology Department
[6] Kantonsspital,Oncology Division
[7] University Hospital Geneva,undefined
[8] University Hospital Lausanne,undefined
[9] University Hospital Basel,undefined
[10] Bürgerspital,undefined
来源：
Breast Cancer Research and Treatment | 2000年 / 59卷
关键词：
breast cancer; cellular immunity; β; -microglobulin; sIL-2r; prognosis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Objective: The association of known prognostic factors with immune cell counts and β2-microglobulin and soluble IL-2 receptor (sIL-2r) serum levels as markers of activation of the immune system was investigated in breastcancer.
引用
收藏
页码：279 / 287
页数：8
相关论文
共 50 条
  • [41] Adjuvant treatment for early breast cancer
    Smith, I
    ANNALS OF ONCOLOGY, 2005, 16 : 182 - 187
  • [42] Optimal timing of adjuvant treatment in patients with early breast cancer
    Necati Alkis
    Ayse G. Durnali
    Ulku Y. Arslan
    Murat Kocer
    Fatih O. Onder
    Saadet Tokluoglu
    Gokhan Celenkoglu
    Sadik Muallaoglu
    Gungor Utkan
    Arife Ulas
    Kadri Altundag
    Medical Oncology, 2011, 28 : 1255 - 1259
  • [43] Decline in cognitive functions in elderly early-stage breast cancer patients after adjuvant treatment
    Lange, M.
    Heutte, N.
    Rigal, O.
    Noal, S.
    Kurtz, J. E.
    Levy, C.
    Allouache, D.
    Rieux, C.
    Lefel, J.
    Clarisse, B.
    Veyret, C.
    Barthelemy, P.
    Longato, N.
    Eustache, F.
    Giffard, B.
    Joly, F.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2015, 29 : 14 - 14
  • [44] BONE HEALTH AND ITS MANAGEMENT IN EARLY STAGE BREAST CANCER PATIENTS COMMENCING ADJUVANT HORMONAL TREATMENT
    Dua, Divyanshu
    Koczwara, Bogda
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2012, 8 : 344 - 344
  • [45] Treatment With Adjuvant Endocrine Therapy for Early-Stage Breast Cancer: Is It Forever?
    Overmoyer, Beth
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (08) : 823 - +
  • [46] Adjuvant chemotherapy and hypofractionated VMAT treatment with SIB for early stage breast cancer
    Franceschini, D.
    De Rose, F.
    Iftode, C.
    D'Agostino, G. R.
    Navarria, P.
    Mancosu, P.
    Fogliata, A.
    Tomatis, S.
    Scorsetti, M.
    RADIOTHERAPY AND ONCOLOGY, 2018, 127 : S700 - S700
  • [47] Patient preferences for adjuvant treatment of early-stage breast cancer.
    Fama, T
    Wood, M
    Muss, H
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 61S - 61S
  • [48] Aromatase inhibitors in the adjuvant treatment of postmenopausal women with early stage breast cancer
    Ligibel, Jennifer A.
    Winer, Eric P.
    WOMENS HEALTH, 2006, 2 (01) : 89 - 97
  • [49] Prognostic factors influencing prognosis in early breast cancer patients
    Najafi, Safa
    Sadeghi, Masoud
    Abasvandi, Fereshteh
    Shajari, Mohammad Reza
    Mohebi, Kamran
    Ghandchi, Helen
    MENOPAUSE REVIEW-PRZEGLAD MENOPAUZALNY, 2019, 18 (02): : 82 - 88
  • [50] Initial treatment and changes in adjuvant endocrine therapy for early stage breast cancer
    Schwartzberg, Lee S.
    Cobb, Patrick
    Senecal, Frank
    Henry, David
    Kulig, Kimary
    Walker, Mark S.
    Houts, Arthur C.
    Stepanski, Edward J.
    BREAST, 2009, 18 (02): : 78 - 83
12345